27,860 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Magnetar Financial LLC

Magnetar Financial LLC purchased a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 27,860 shares of the company’s stock, valued at approximately $1,737,000. Magnetar Financial LLC owned about 0.08% of TransMedics Group as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMDX. Hager Investment Management Services LLC purchased a new stake in TransMedics Group during the 4th quarter valued at $33,000. Sachetta LLC purchased a new stake in TransMedics Group during the 4th quarter valued at $40,000. AlphaQuest LLC purchased a new stake in TransMedics Group during the 4th quarter valued at $52,000. Quarry LP boosted its stake in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares during the last quarter. Finally, National Bank of Canada FI boosted its stake in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Robert W. Baird lowered their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Oppenheimer reissued an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. Piper Sandler lowered their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $68.84 on Friday. The firm has a 50 day moving average of $68.12 and a 200 day moving average of $91.74. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of 73.23 and a beta of 2.12.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.